CREB5 and Alzheimer disease: Overall, the findings suggest miR‐32533 as a regulator of Aβ metabolism, oxidative stress, and neuroinflammation, establishing the miR‐32533/CREB5 signaling pathways as potential therapeutic targets for combating Aβ accumulation and cognitive deficits in AD.